Compare · LEXX vs LLY
LEXX vs LLY
Side-by-side comparison of Lexaria Bioscience Corp. (LEXX) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LEXX and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.09T, about 159020.7x LEXX ($6.8M).
- Over the past year, LEXX is down 81.2% and LLY is up 53.2% - LLY leads by 134.4 points.
- LLY has been more active in the news (10 items in the past 4 weeks vs 8 for LEXX).
- LLY has more recent analyst coverage (25 ratings vs 0 for LEXX).
- Company
- Lexaria Bioscience Corp.
- Eli Lilly and Company
- Price
- $3.44+10.61%
- $1152.46-0.00%
- Market cap
- $6.8M
- $1.09T
- 1M return
- -70.87%
- -10.00%
- 1Y return
- -81.20%
- +53.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 10
- Recent ratings
- 0
- 25
Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LEXX
- Lexaria Updates Financial Position
- Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
- Lexaria Bioscience Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
- Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Lexaria Bioscience Corp. filed SEC Form 8-K: Other Events
- Lexaria Receives USD$2.6 Million Tax Rebate Payment
- DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
- Lexaria Bioscience Corp. filed SEC Form 8-K: Other Events
- Lexaria Enters a Material Transfer Agreement With PegBio
Latest LLY
- U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
- Eli Lilly upgraded by Berenberg with a new price target
- Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
- EVP, Global Quality Seymour Melissa gifted 29 shares, decreasing direct ownership by 3% to 1,038 units (SEC Form 4)
- Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study